Canopy Growth (TSX:WEED) Smoked on Earnings: Should You Buy on Weakness?

Should investors buy Canopy Growth Corp (TSX:WEED)(NYSE:CGC) on its recent post-earnings dip? Or is it time to take profits for good?

| More on:
Cannabis stocks have fallen.
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Don’t say you weren’t warned!

Canopy Growth (TSX:WEED)(NYSE:CGC) got clobbered 7.6% on Friday following the reveal of a weaker-than-expected quarterly report that showed a big loss together with swelling operating expenses. Fellow Fool contributor Karen Thomas did a top-notch job of reviewing the results. In this piece, we’ll try to determine whether it still makes sense for the average Canadian investor to hold shares of the marijuana giant as it loses steam.

You need to spend money to make money, right?

Canopy CEO Bruce Linton’s tone shouldn’t have come as a surprise to investors. Every time Canopy reports a number that’s deep in the red, Linton shrugs it off and provides commentary on his views of the longer-term picture and why near-term losses aren’t a big deal in the grander scheme of things.

“You need to use that capital to build scale. And we did,” said Linton in Canopy’s conference call.

To Linton, it’s all about short-term pain for long-term gain, and with his foot on the gas, he’ll likely have no problem telling prospective marijuana investors to “go buy a bank” if a dividend or lower capital spending is what they seek from his hyper-growth firm.

In terms of profitability, Linton also told analysts that Canopy “would have been a nice, tidy little company, probably quite profitable” if the firm “had stayed” in its high-margin state.

Linton sees margins racing higher at year-end as investments begin paying off, while higher-margin edibles sales start coming into the equation. With Canopy readying to jump on the edibles bandwagon later this year, many investors are wondering if big-name cannabis kings like Canopy could stand to experience another exponential rally.

Should you take Linton’s word for it?

While I am a fan of Linton’s aggressive spending, I also think Canopy has the least upside relative to its peers for many reasons that I outlined in past pieces. Moreover, legal edibles sales will be an industry-wide boon to margins, and although Canopy is getting locked and loaded, so too are other pot players that’ve posted better margins of late.

Sure, Canopy has a deep-pocketed dance partner in its corner and may be perceived as one of the “safer” bets in the space, but investors have to remember that Canopy trades at nearly 80 times sales, making it one of the most expensive stocks on the planet. Canopy could halve several times over and still be considered “expensive” through the eyes of fundamental analysts. By comparison, Canopy makes Shopify, one of Canada’s highest-flying stocks, look like a cheap stock with its hefty 30 times sales multiple.

I can’t say I’m an advocate of buying shares of Canopy after its latest dip. We’re almost a year into legalization, and the “edibles tailwind” that some investors are growing excited about may not be enough to reverse the negative momentum faced by the industry, especially should Canada face an unexpected cannabis oversupply problem going into year-end.

Canopy is a premier cannabis player, but it’s also priced like one. The recent 7.6% drop in Canopy shares would have me worried sick to be an investor.

Stay hungry. Stay Foolish.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joey Frenette has no position in any of the stocks mentioned. Tom Gardner owns shares of Shopify. The Motley Fool owns shares of Shopify and Shopify. Shopify is a recommendation of Stock Advisor Canada.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »